Vericel (VCEL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 Mar, 2026Executive summary
Annual Meeting of Shareholders scheduled for April 29, 2026, to be held virtually at 9:00 a.m. ET.
Shareholders can vote online, by mail, or during the virtual meeting using a control number.
Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are available online or by request.
Voting matters and shareholder proposals
Election of seven directors: Robert L. Zerbe, Alan L. Rubino, Heidi Hagen, Kevin F. McLaughlin, Paul K. Wotton, Dominick C. Colangelo, and Lisa Wright.
Advisory vote to approve named executive officers' compensation.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other matters properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Latest events from Vericel
- Record revenue, strong growth, and robust governance set the stage for sustained expansion.VCEL
Proxy filing19 Mar 2026 - MACI and burn care drive robust growth, with sales force and Arthro launch boosting momentum.VCEL
Leerink Global Healthcare Conference 202610 Mar 2026 - MACI and MACI Arthro drive robust growth, supported by new manufacturing and expanding markets.VCEL
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Record Q4 revenue and profit growth, with strong MACI performance and robust 2026 outlook.VCEL
Q4 202526 Feb 2026 - Q1 outperformance drives raised guidance; MACI arthroscopic launch and margin growth set for 2025.VCEL
2024 Truist Securities MedTech Conference3 Feb 2026 - Record Q2 revenue and margin gains led to raised profitability guidance for 2024.VCEL
Q2 20242 Feb 2026 - Record growth and new product launches position the business for continued expansion.VCEL
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - MACI Arthro and NexoBrid pediatric approvals drive growth and expand market reach.VCEL
Morgan Stanley 22nd Annual Global Healthcare Conference21 Jan 2026 - Record Q3 revenue and margin growth, with FDA approvals and strong outlook for continued gains.VCEL
Q3 202416 Jan 2026